Research Article
A Novel Scoring System Based on the Level of HDL-C for Predicting the Prognosis of t-DLBCL Patients: A Single Retrospective Study
Table 2
Response to treatment of the t-DLBCL patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
R, rituximab; OS, overall survival; PFS, progression free survival; CR, complete remission; PR, partial remission; OR, overall response; NA, not available; NR, not reached; NS, not significant. Details in the OS of the 6 patients: (1) 1.114 years, alive; (2) 0.194 years, dead; (3) 1.592 years, dead; (4) 4.772 years, alive; (5) 1.444 years, alive; (6) 0.372 years, dead. Details in the PFS of the 6 patients: (1) 1.114 years, PR; (2) 0.194 years, dead; (3) 1.028 years, PD; (4) 0.675 years, PD; (5) 1.444 years, PR; (6) 0.303 years, PD. |